On a GAAP basis, revenue for Qorvo’s fiscal 2026 second quarter was $1.1 billion, gross margin was 47.0%, operating income was $157.7 million, and diluted earnings per share was $1.28. On a non-GAAP ...
Q3 2025 Earnings Call Transcript November 5, 2025 Anika Therapeutics, Inc. misses on earnings expectations. Reported EPS is $ ...
Introduction Excessive opioid prescribing after surgery can lead to adverse events and exacerbate the opioid crisis. Patients undergoing outpatient breast surgery are often prescribed opioids to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback